Free Trial

Yanni Souroutzidis Analyst Performance

Analyst at Cantor Fitzgerald

Yanni Souroutzidis is a stock analyst at Cantor Fitzgerald across a range of sectors, covering 2 publicly traded companies. Over the past year, Yanni Souroutzidis has issued 2 stock ratings, including and buy recommendations. While full access to Yanni Souroutzidis' proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Yanni Souroutzidis' coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
2 Last 0 Years
Buy Recommendations
100.00% 2 Buy Ratings
Companies Covered
2 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy100.0%2 ratings
Hold0.0%0 ratings
Sell0.0%0 ratings

the majority (100.0%) have been Buy recommendations.

Best & Worst Calls

This analyst does not have any ratings with enough history to determine best and worst calls.

Exchange Coverage

ExchangePercentageCount
NASDAQ
100.0% of companies on NASDAQ
2 companies

Yanni Souroutzidis, an analyst at Cantor Fitzgerald, currently covers 2 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Miscellaneous
1 company
50.0%
Medical
1 company
50.0%

Yanni Souroutzidis of Cantor Fitzgerald specializes in stock coverage within the sector, with additional focus on Medical companies.

Coverage Industries

IndustryPercentage
Miscellaneous
1 company
50.0%
MED - DRUGS
1 company
50.0%

Yanni Souroutzidis' Ratings History at Cantor Fitzgerald

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
MSLE
Satellos Bioscience
3/11/2026Initiated Coverage$9.54Overweight
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
2/5/2026Initiated Coverage$6.30Overweight